TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16236684

Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 32

Group type: COMPARATOR
Intervention: Sevoflurane and Isoflurane
Number of subjects: 32
Study: 12837043

Group type: EXPERIMENTAL
Intervention: Asthalin
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Salomol
Number of subjects: 21

Group type: COMPARATOR
Intervention: Ventolin
Number of subjects: 21
Study: 9694052

Group type: EXPERIMENTAL
Intervention: sICAM‐1 levels in SpA patients
Number of subjects: 25

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 25

Group type: COMPARATOR
Intervention: Patients with rheumatoid arthritis (RA)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Correlation of sICAM‐1 with inflammatory parameters in SpA
Number of subjects: 25

Group type: COMPARATOR
Intervention: Correlation of sICAM‐1 with inflammatory parameters in RA
Number of subjects: 25
Study: 8081529

Group type: EXPERIMENTAL
Intervention: Sustained-release magnesium chloride (Slo-Mag), 384 mg/d
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 2596748

Group type: EXPERIMENTAL
Intervention: Cervical extraoral force
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Combi extraoral force
Number of subjects: 200

Group type: COMPARATOR
Intervention: No-headgear
Number of subjects: 200
Study: 4552591

Group type: EXPERIMENTAL
Intervention: Active drug (bethanidine, debrisoquine, guanethidine)
Number of subjects: 137

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 137
Study: 30880108

Group type: EXPERIMENTAL
Intervention: iStent inject implantation (Model G2‐M‐IS)
Number of subjects: 505

Group type: COMPARATOR
Intervention: Cataract surgery alone (control group)
Number of subjects: 505
Study: 28968163

Group type: EXPERIMENTAL
Intervention: Abemaciclib plus a nonsteroidal aromatase inhibitor (150 mg twice daily continuous schedule)
Number of subjects: 493

Group type: EXPERIMENTAL
Intervention: Abemaciclib plus a nonsteroidal aromatase inhibitor
Number of subjects: 493

Group type: EXPERIMENTAL
Intervention: Abemaciclib
Number of subjects: 493
Study: 26459346

Group type: EXPERIMENTAL
Intervention: HRV biofeedback training
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 41
Study: 24139456

Group type: EXPERIMENTAL
Intervention: Bilateral internal jugular vein sheaths
Number of subjects: 117

Group type: COMPARATOR
Intervention: Percutaneous superior vena cava cannula
Number of subjects: 117
Study: 22975340

Group type: EXPERIMENTAL
Intervention: Dengue vaccine (3 injections at months 0, 6, and 12)
Number of subjects: 4002

Group type: COMPARATOR
Intervention: Control (rabies vaccine or placebo)
Number of subjects: 4002
Study: 19776293

Group type: EXPERIMENTAL
Intervention: IDX899
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: IDX989
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: IDX899 and IDX989
Number of subjects: 8
Study: 17261206

Group type: EXPERIMENTAL
Intervention: Active impedance threshold device
Number of subjects: 19

Group type: COMPARATOR
Intervention: Sham impedance threshold device
Number of subjects: 19
Study: 15111749

Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.15%
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 11174492

Group type: EXPERIMENTAL
Intervention: Corticosteroids
Number of subjects: 1400
Study: 10449888

Group type: EXPERIMENTAL
Intervention: valsartan (80 mg/160 mg q.d.)
Number of subjects: 69

Group type: COMPARATOR
Intervention: atenolol (50 mg/100 mg q.d.)
Number of subjects: 69
Study: 7869205

Group type: EXPERIMENTAL
Intervention: Erythropoietin (Epo) 200 units/kg per day
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 2218713

Group type: EXPERIMENTAL
Intervention: Posterior distraction using pedicle instrumentation (AO fixateur interne)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Anterior decompression and instrumentation (Kostuik‐Harrington device)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Anterior surgery
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Posterior surgery
Number of subjects: 40
Study: 577626

Group type: EXPERIMENTAL
Intervention: Streptokinase ('Kabikinase') followed by oral anticoagulant therapy
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Ancrod ('Arvin') for 6 days followed by oral anticoagulant therapy
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group (oral anticoagulant therapy only)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Ancrod treatment
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Streptokinase and ancrod treatments
Number of subjects: 26
Study: 30956267

Group type: EXPERIMENTAL
Intervention: Bisoprolol 5 mg/day
Number of subjects: 217

Group type: COMPARATOR
Intervention: Carvedilol 20 mg/day
Number of subjects: 217
Study: 28253389

Group type: EXPERIMENTAL
Intervention: Drug-induced sleep endoscopy with polygraphic monitoring (DISE-PG)
Number of subjects: 50
Study: 25888774

Group type: EXPERIMENTAL
Intervention: rhPDGF‐BB/β‐TCP (Augment®)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Closed reduction and external fixation alone
Number of subjects: 40
Study: 24010992

Group type: EXPERIMENTAL
Intervention: 0.3 mg sublingual nitroglycerin tablet
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: 0.6 mg sublingual nitroglycerin tablet
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: 20 mg tablet of isosorbide mononitrate
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: 160 mg nitroglycerin transdermal patch (used for 8 h)
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: 15 mg of nitroglycerin ointment
Number of subjects: 420
Study: 21293309

Group type: EXPERIMENTAL
Intervention: Atomoxetine (ATX) 80 mg/day
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 19298581

Group type: EXPERIMENTAL
Intervention: Esomeprazole 20 mg once daily for 6 months
Number of subjects: 2766

Group type: COMPARATOR
Intervention: Pantoprazole 20 mg once daily for 6 months
Number of subjects: 2766
Study: 18257347

Group type: EXPERIMENTAL
Intervention: Heat electroacupuncture instrument with Chinese herb iontophoresis, combined with Meloxicam, Salazosulfamide, and Methotrexate
Number of subjects: 96

Group type: COMPARATOR
Intervention: Simple western medicine
Number of subjects: 96
Study: 15134122

Group type: EXPERIMENTAL
Intervention: HIV prevention messages disseminated through community popular opinion leaders (CPOLs); specific details on dosage and duration not available.
Number of subjects: 100
Study: 11483788

Group type: EXPERIMENTAL
Intervention: Daily antiinflammatory medications (mostly cromolyn sodium)
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: Moderate to severe persistent asthma
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: Daily antiinflammatory medications
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: Quality asthma home management measures
Number of subjects: 219
Study: 9891542

Group type: EXPERIMENTAL
Intervention: Multi-drug regimens
Number of subjects: 2100

Group type: COMPARATOR
Intervention: Single agent treatment (usually BCNU)
Number of subjects: 2100
Study: 1284158

Group type: EXPERIMENTAL
Intervention: Gallopamil 50 mg t.i.d. (days 8-14)
Number of subjects: 25
Study: 6531964

Group type: EXPERIMENTAL
Intervention: Suckling mouse brain vaccine (SMBV)
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Fetal bovine kidney vaccine (FBKV) administered subcutaneously
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Fetal bovine kidney vaccine (FBKV) administered intramuscularly
Number of subjects: 136
Study: 30095354

Group type: EXPERIMENTAL
Intervention: Botulinum toxin A (BoNT-A) injection plus rehabilitation therapy
Number of subjects: 30

Group type: COMPARATOR
Intervention: Rehabilitation therapy alone
Number of subjects: 30
Study: 30089525

Group type: EXPERIMENTAL
Intervention: Whey protein supplementation with supervised exercise for 12 weeks, three times a week.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo with supervised exercise for 12 weeks, three times a week.
Number of subjects: 0
Study: 26963844

Group type: EXPERIMENTAL
Intervention: Gabapentin (3600 mg daily)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108
Study: 25386212

Group type: EXPERIMENTAL
Intervention: Fentanyl and 2% lidocaine with 1:80000 epinephrine
Number of subjects: 61

Group type: COMPARATOR
Intervention: Normal saline and 2% lidocaine with 1:80000 epinephrine
Number of subjects: 61
Study: 23084383

Group type: EXPERIMENTAL
Intervention: Early treatment for retinopathy of prematurity (ROP)
Number of subjects: 718

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 718
Study: 19342934

Group type: EXPERIMENTAL
Intervention: Full-endoscopic interlaminar and transforaminal technique
Number of subjects: 87

Group type: COMPARATOR
Intervention: Microsurgical technique
Number of subjects: 87
Study: 17438101

Group type: EXPERIMENTAL
Intervention: Interferon-alpha2b therapy
Number of subjects: 179

Group type: COMPARATOR
Intervention: Not applicable (healthy controls)
Number of subjects: 179

Group type: COMPARATOR
Intervention: Not applicable (proinflammatory cytokines levels)
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: Bayesian Network algorithm classification
Number of subjects: 179
Study: 15185127

Group type: EXPERIMENTAL
Intervention: TEP repair (n = 40)
Number of subjects: 80

Group type: COMPARATOR
Intervention: PPOR (n = 40)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Both TEP and PPOR
Number of subjects: 80
Study: 11451596

Group type: EXPERIMENTAL
Intervention: 0.2 mg/kg/day rhGH during hospitalization
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group (no rhGH)
Number of subjects: 38
Study: 10806764

Group type: EXPERIMENTAL
Intervention: Nao Yi-an granule (Chinese medicine group, CMG)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Western medicine (western medicine group, WMG)
Number of subjects: 40
Study: 7633009

Group type: EXPERIMENTAL
Intervention: Famotidine 20 mg
Number of subjects: 18

Group type: COMPARATOR
Intervention: NaCl 0.9% placebo
Number of subjects: 18
Study: 2575983

Group type: EXPERIMENTAL
Intervention: epanolol 200mg once daily
Number of subjects: 529

Group type: COMPARATOR
Intervention: nifedipine 20mg twice daily
Number of subjects: 529
Study: 386045

Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30866465

Group type: EXPERIMENTAL
Intervention: Digital impression group (DIG)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Conventional impression group (CIG)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both groups (DIG and CIG)
Number of subjects: 50
Study: 28701090

Group type: EXPERIMENTAL
Intervention: Transference Focused Psychotherapy (TFP) combined with group skills training from Dialectic Behavior Therapy (DBT)
Number of subjects: 0
Study: 26553085

Group type: EXPERIMENTAL
Intervention: Intravenous Dexamethasone (8 mg)
Number of subjects: 172

Group type: COMPARATOR
Intervention: Control (distilled water, 8 mg)
Number of subjects: 172
Study: 23934515

Group type: EXPERIMENTAL
Intervention: Relaxation training according to the YIDL system (1-hour group session per day for 1 week, followed by 3 weeks of home practice with audiocassette recordings)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Standard physiotherapy (same for both groups)
Number of subjects: 32
Study: 22279697

Group type: EXPERIMENTAL
Intervention: Literal adherence for ordering a lipoprotein profile
Number of subjects: 7745

Group type: EXPERIMENTAL
Intervention: Literal adherence for pharmacotherapy initiations
Number of subjects: 7745

Group type: EXPERIMENTAL
Intervention: Literal adherence for drug up-titrations
Number of subjects: 7745

Group type: EXPERIMENTAL
Intervention: Literal adherence for referrals for specialist consultation
Number of subjects: 7745

Group type: EXPERIMENTAL
Intervention: Substitute adherence for drug up-titrations
Number of subjects: 7745

Group type: EXPERIMENTAL
Intervention: Substitute adherence for referrals for consultation
Number of subjects: 7745
Study: 19457255

Group type: EXPERIMENTAL
Intervention: WPS-RA at week 24 for ACR20 responders
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: WPS-RA at week 24 for HAQ-DI responders
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: WPS-RA at week 24 for non-responders
Number of subjects: 220

Group type: COMPARATOR
Intervention: WPS-RA for subjects with lower HAQ-DI or SF-36 scores
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: WPS-RA for work absenteeism and days with outside help
Number of subjects: 220
Study: 16490876

Group type: EXPERIMENTAL
Intervention: 200-microg dose of mometasone furoate nasal spray administered once daily
Number of subjects: 310

Group type: EXPERIMENTAL
Intervention: 200-microg dose of mometasone furoate nasal spray administered twice daily
Number of subjects: 310

Group type: COMPARATOR
Intervention: Matching placebo administered in the morning and evening
Number of subjects: 310
Study: 15214595

Group type: EXPERIMENTAL
Intervention: HAI floxuridine
Number of subjects: 0

Group type: COMPARATOR
Intervention: HAI fluorouracil (5-FU)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Systemically administered 5-FU
Number of subjects: 0

Group type: COMPARATOR
Intervention: HAI chemotherapy
Number of subjects: 0
Study: 11141713

Group type: EXPERIMENTAL
Intervention: Preventive management (0.45% saline intravenously, mannitol 20% 250 mL i.v., furosemide 80 mg i.v., dopamine 3 g/Kg/min i.v.)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 16250725

Group type: EXPERIMENTAL
Intervention: Behavioral treatment package
Number of subjects: 39
Study: 7930276

Group type: EXPERIMENTAL
Intervention: Amlodipine 5 mg/day (increased to 10 mg/day after 4 weeks)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 250
Study: 2843341

Group type: EXPERIMENTAL
Intervention: Hydralazine
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Lisinopril + HCTZ
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: HCTZ
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Lisinopril
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Nitrendipine
Number of subjects: 77

Group type: COMPARATOR
Intervention: All other agents
Number of subjects: 77
Study: 31635497

Group type: EXPERIMENTAL
Intervention: BCX7353 (oral plasma kallikrein inhibitor), taken as an oral capsule, once daily.
Number of subjects: 0
Study: 29231583

Group type: EXPERIMENTAL
Intervention: Acupoint plaster therapy with midnight-noon ebb-flow hour-prescription method
Number of subjects: 76

Group type: COMPARATOR
Intervention: Traditional acupoint plaster therapy
Number of subjects: 76
Study: 25926413

Group type: COMPARATOR
Intervention: Iron-Folic Acid (IFA)
Number of subjects: 869

Group type: COMPARATOR
Intervention: Micronutrient Mix (MMN)
Number of subjects: 869

Group type: EXPERIMENTAL
Intervention: Small-Quantity Lipid-Based Nutrient Supplements (SQ-LNS)
Number of subjects: 869
Study: 23291612

Group type: EXPERIMENTAL
Intervention: Ethanol extract of Hedyotis diffusa Willd (EEHDW)
Number of subjects: 1
Study: 21544006

Group type: EXPERIMENTAL
Intervention: Pulsatile perfusion
Number of subjects: 111

Group type: COMPARATOR
Intervention: Nonpulsatile perfusion
Number of subjects: 111
Study: 19200622

Group type: EXPERIMENTAL
Intervention: Tamsulosin plus ibuprofen and oxycodone
Number of subjects: 80

Group type: COMPARATOR
Intervention: Ibuprofen and oxycodone alone
Number of subjects: 80
Study: 17405199

Group type: EXPERIMENTAL
Intervention: Transdermal anaesthesia using EMLA applied transcutaneously 120 minutes prior to the operation (Group A)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Local infiltration anaesthesia using lidocaine (Group B)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Transdermal anaesthesia using EMLA (Group A)
Number of subjects: 50
Study: 15572497

Group type: EXPERIMENTAL
Intervention: Prospective paper hot flush diary
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Electronic event markers
Number of subjects: 55

Group type: COMPARATOR
Intervention: Biolog ambulatory sternal skin conductance monitor
Number of subjects: 55
Study: 10991932

Group type: EXPERIMENTAL
Intervention: L-NAME, 1 micromol per nostril every 30 min for 6 h
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: L-arginine, 30 micromol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: D-NAME, 1 micromol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: L-NMMA, 1 micromol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PAF, 60 microg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Repeated administration of L-NAME, 1 micromol
Number of subjects: 0
Study: 9082864

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (Awake data)
Number of subjects: 30
Study: 8349916

Group type: EXPERIMENTAL
Intervention: Electrical stimulation
Number of subjects: 0
Study: 3546155

Group type: EXPERIMENTAL
Intervention: 400 mg ofloxacin
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: 600 mg ofloxacin
Number of subjects: 78
Study: 29777864

Group type: EXPERIMENTAL
Intervention: Home‐based dietary counseling +800 mg/day DHA supplementation
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: 800 mg/day DHA
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Home‐based dietary counseling +200 mg/day DHA
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: 200 mg/day DHA
Number of subjects: 1000
Study: 27487082

Group type: EXPERIMENTAL
Intervention: Cigarette cue exposure
Number of subjects: 90

Group type: COMPARATOR
Intervention: Neutral cue exposure
Number of subjects: 90
Study: 24939437

Group type: EXPERIMENTAL
Intervention: α-Tocopherol (400 IU/day)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: α-Lipoic acid (ALA) (100 mg/day)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 93
Study: 23010871

Group type: EXPERIMENTAL
Intervention: Changes in temperature and humidity associated with enrollment event
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gender, region, and history of stroke
Number of subjects: 0
Study: 21992977

Group type: EXPERIMENTAL
Intervention: Lactobacillus crispatus CTV-05 (LACTIN-V) applied vaginally once daily for 5 days, followed by weekly application over 2 weeks
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo applied vaginally once daily for 5 days, followed by weekly application over 2 weeks
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Lactobacillus crispatus CTV-05 (LACTIN-V)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Endogenous L. crispatus presence
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Vaginal intercourse during the study
Number of subjects: 24
Study: 18507266

Group type: EXPERIMENTAL
Intervention: Resistance training
Number of subjects: 59

Group type: COMPARATOR
Intervention: Aerobic exercise
Number of subjects: 59
Study: 16403712

Group type: EXPERIMENTAL
Intervention: CorX system (group A)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Conventional CPB system (group B)
Number of subjects: 81
Study: 14634680

Group type: EXPERIMENTAL
Intervention: PEG‐OB protein (80 mg) administered subcutaneously weekly for 6 weeks
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo administered subcutaneously weekly for 6 weeks
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: PEG‐OB protein (80 mg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 10718694

Group type: EXPERIMENTAL
Intervention: Primary care-based physical activity counseling
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tailored interventions with written materials
Number of subjects: 0

Group type: COMPARATOR
Intervention: Primary care-based physical activity interventions
Number of subjects: 0
Study: 8877657

Group type: EXPERIMENTAL
Intervention: Electric toothbrush (Braun/Oral-B Plak Control)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Manual toothbrush
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Electric toothbrush (Rotadent)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Electric toothbrush (Interplak)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Electric toothbrush (Braun)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: All toothbrushes
Number of subjects: 20
Study: 1713999

Group type: EXPERIMENTAL
Intervention: Intracoronary gallopamil 3.0 micrograms/kg
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Intracoronary gallopamil 1.5 micrograms/kg
Number of subjects: 14

Group type: COMPARATOR
Intervention: Intracoronary saline
Number of subjects: 14
Study: 6109119

Group type: EXPERIMENTAL
Intervention: Dry artificial lung surfactant (one dose)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (33 subjects)
Number of subjects: 22
Study: 30649276

Group type: EXPERIMENTAL
Intervention: CFA (Complex Fractionated Atrial Electrogram-guided Focal Ablation)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: CLA (CFAE-guided Linear Ablation)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: CFA
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: CLA
Number of subjects: 150
Study: 28633874

Group type: EXPERIMENTAL
Intervention: Dual-energy x-ray absorptiometry (DXA)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Bioelectrical impedance analysis (BIA)
Number of subjects: 48
Study: 26370443

Group type: EXPERIMENTAL
Intervention: 600 mcg misoprostol
Number of subjects: 748

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 748
Study: 23469256

Group type: EXPERIMENTAL
Intervention: Pregabalin (150-300 mg BID)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study: 21441812

Group type: EXPERIMENTAL
Intervention: 5-aminosalicylic acid (5-ASA) alone
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: 5-aminosalicylic acid (5-ASA) in combination with a probiotic
Number of subjects: 2

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 2
Study: 20925776

Group type: EXPERIMENTAL
Intervention: Delirium prevention protocol implemented on intervention unit patients
Number of subjects: 70

Group type: COMPARATOR
Intervention: Usual care without delirium protocol
Number of subjects: 70
Study: 17407458

Group type: EXPERIMENTAL
Intervention: Milk-odour condition
Number of subjects: 13

Group type: COMPARATOR
Intervention: Water-control condition
Number of subjects: 13
Study: 15234488

Group type: EXPERIMENTAL
Intervention: Custom-made insoles
Number of subjects: 20

Group type: COMPARATOR
Intervention: Flat insoles
Number of subjects: 20